Bulk Pharmaceutical API Sources for RENOGRAFIN-60

Bulk Pharmaceutical API Sources for RENOGRAFIN-60

Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem		B1260098
THE BioTek		bt-1592376
RR Scientific		R6365821
EvitaChem		evt-1592376

Bulk Active Pharmaceutical Ingredient (API) Sources for: RENOGRAFIN-60

Last updated: July 30, 2025

Introduction

Renografin-60, a commonly used iodinated contrast agent, primarily serves radiographic imaging procedures. As with many medical compounds, its efficacy and safety hinge on sourcing high-quality Active Pharmaceutical Ingredient (API). Understanding the landscape of bulk API suppliers for Renografin-60 is critical for pharmaceutical manufacturers, procurement specialists, and healthcare providers aiming to ensure compliance with regulatory standards, cost-effectiveness, and reliable supply chains.

Chemical Composition and Manufacturing Context

Renografin-60 contains diatrizoate meglumine and diatrizoate sodium, both iodine-containing compounds that facilitate contrast in imaging. The API encompasses these iodinated salts, requiring sophisticated synthesis, purification, and quality assurance processes. Raw material suppliers must adhere to Good Manufacturing Practices (GMP) and international standards such as USP or EP, reflecting stringent regulatory scrutiny.

Global API Suppliers for Renografin-60

The API supply landscape is concentrated among specialized chemical manufacturers with expertise in iodine chemistry and radiocontrast agents. Key sources include:

1. Bayer HealthCare Pharmaceuticals

   Bayer is a leading player in the production of iodinated contrast media. Historically, the company has supplied APIs used in formulations like Renografin-60. Their extensive R&D capabilities enable scalable synthesis and rigorous quality standards. Bayer's global presence ensures reliable distribution channels.

2. Bracco Imaging

   An established manufacturer of radiology agents, Bracco produces iodine-based contrast media, including active ingredients similar to those in Renografin-60. Their vertically integrated supply chain guarantees control over raw materials and API quality.

3. Jiangsu Hengrui Medicine Co., Ltd.

   A prominent Chinese pharmaceutical company, Hengrui has expanded into the iodine-based API sector. Their GMP-certified facilities produce iodinated compounds for global export, supported by China's favorable manufacturing policies and robust biotech infrastructure.

4. Meyab Group

   Specializing in iodine chemistry, Meyab offers APIs for contrast media, including diatrizoate derivatives. Their focus on purity and batch consistency aligns with regulatory expectations.

5. Seikagaku Corporation

   Although primarily known for pharmaceutical and biotech products, Seikagaku has invested in iodine chemistry facilities capable of supplying API-grade diatrizoates.

Regional API Production Hubs

• Asia-Pacific Region: Countries like China, India, and South Korea host numerous API manufacturers offering cost-effective solutions. Regulatory standards vary, but GMP compliance is increasingly common among reputable producers.

• Europe & North America: These regions maintain rigorous quality standards, with Bayer, Bracco, and other key pharma firms setting benchmarks for API production.

Supply Chain Dynamics and Considerations

• Regulatory Compliance: Suppliers must adhere to strict GMP guidelines by agencies like the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency). Validation reports, batch records, and stability data are critical.

• Quality Certifications: ISO certifications (e.g., ISO 9001, ISO 13485) further corroborate supplier reliability.

• Regulatory Approvals: Procurement must verify that APIs are approved or can be approved in target markets, capturing data on certificates of analysis (COA), pharmacopoeial compliance, and batch potency.

• Supply Reliability: Given the critical role of contrast agents in diagnostics, continuous supply without interruption is paramount. Diversifying sources and maintaining buffer stocks mitigate risks.

• Pricing and Lead Times: Market competition influences API pricing. South Asian manufacturers often present competitive rates with shorter lead times due to manufacturing scale.

Challenges in Sourcing API for Renografin-60

• Quality Risks: Variability in raw materials and synthesis processes impacts batch consistency.

• Regulatory Barriers: Cross-border API transfers require rigorous documentation and compliance verification.

• Supply Disruptions: Geopolitical issues, pandemics, or raw material shortages can affect production continuity.

• Environmental & Ethical Standards: Increasing emphasis on sustainable practices influences supplier selection, especially regarding iodine supply chain transparency.

Future Outlook

Given the global demand for radiological diagnostics, API production capacity for iodinated contrast agents like Renografin-60 is poised for expansion. Emerging manufacturers across Asia aim to meet quality standards aligned with Western regulatory agencies, broadening the supplier base. Moreover, innovation in synthetic pathways promises more cost-effective and environmentally friendly API production.

Conclusion

Sourcing bulk API for Renografin-60 involves evaluating manufacturing expertise, regulatory compliance, supply reliability, and cost. Leading global manufacturers such as Bayer and Bracco stand out for quality and regulatory trust, while regional suppliers in Asia provide cost-effective alternatives. Careful vendor qualification and continuous supply chain monitoring are vital to ensure uninterrupted access to high-quality API, supporting the manufacturing of safe and effective contrast agents.

---

Key Takeaways

• Leading Suppliers: Bayer and Bracco dominate the high-quality API segment for Renografin-60; regional suppliers in China and India provide additional options.

• Regulatory Assurance: Verifying GMP compliance, certifications, and documentation is essential to meet international standards.

• Supply Chain Strategies: Diversifying suppliers and maintaining safety stocks mitigate risks associated with manufacturing disruptions.

• Market Trends: Growing manufacturing capacity in Asia aligns with increasing demand for iodinated contrast media globally.

• Sustainability Focus: Future API sourcing will more heavily factor in environmental impact and ethical sourcing practices.

---

FAQs

1. What are the primary raw materials used in the API for Renografin-60?
The API consists mainly of diatrizoate meglumine and diatrizoate sodium, iodine-containing salts produced via complex chemical synthesis involving iodine and organic intermediates.

2. Which regions are most reliable for sourcing high-quality API for Renografin-60?
Europe and North America, with established manufacturers like Bayer and Bracco, offer highly regulated APIs. Asia-Pacific, especially China and India, provide cost-effective alternatives with increasing GMP compliance.

3. How do regulatory standards impact API supplier selection?
Suppliers must demonstrate adherence to GMP, provide certificates of analysis, and meet pharmacopoeial specifications to ensure API quality and market approval.

4. What are common challenges in sourcing API for iodinated contrast agents?
Ensuring consistent quality, navigating regulatory approval processes, supply chain disruptions, and environmental or ethical concerns in raw material sourcing are key challenges.

5. How is the API market for Renografin-60 expected to evolve?
The market is expected to grow with expanding manufacturing capacity in Asia and ongoing innovations in synthesis technology, emphasizing sustainability and cost-efficiency.

---

Sources

1. [1] Bayer AG — Pharmaceutical API manufacturing overview.
2. [2] Bracco Imaging — API and contrast media production standards.
3. [3] Chinese pharmaceutical industry reports on iodine API production.
4. [4] Regulatory guidelines for GMP compliance (FDA, EMA).
5. [5] Market analysis reports on radiocontrast agents and their APIs.